| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.52 |
| 52 Week High | US$2.77 |
| 52 Week Low | US$1.16 |
| Beta | 1.3 |
| 1 Month Change | -4.18% |
| 3 Month Change | -8.72% |
| 1 Year Change | -27.01% |
| 3 Year Change | -70.12% |
| 5 Year Change | -72.01% |
| Change since IPO | -97.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| CU2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.5% | 2.1% | 0.5% |
| 1Y | -27.0% | -8.4% | 1.3% |
Price Volatility
| CU2 volatility | |
|---|---|
| CU2 Average Weekly Movement | 11.8% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 631 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CU2 fundamental statistics | |
|---|---|
| Market cap | €280.53m |
| Earnings (TTM) | -€34.95m |
| Revenue (TTM) | €145.77m |
1.9x
P/S Ratio-8.0x
P/E RatioIs CU2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU2 income statement (TTM) | |
|---|---|
| Revenue | US$156.37m |
| Cost of Revenue | US$69.97m |
| Gross Profit | US$86.40m |
| Other Expenses | US$123.89m |
| Earnings | -US$37.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 55.25% |
| Net Profit Margin | -23.98% |
| Debt/Equity Ratio | 149.3% |
How did CU2 perform over the long term?
See historical performance and comparison